Targeting NLRP3 Inflammasome Activation in Heart Failure: A Promising Therapeutic Strategy

Background: Heart failure (HF) is a leading cause of morbidity and mortality worldwide. Despite therapeutic advances targeting neurohormonal pathways, a large subset of patients exhibit persistent inflammation that drives disease progression. Among the innate immune pathways implicated, the NLRP3 inflammasome has emerged as a central node linking cardiac stress to maladaptive remodeling. Upon activation by danger-associated molecular patterns (DAMPs), NLRP3 promotes caspase-1 activation, pyroptotic cell death, and release of pro-inflammatory cytokines, particularly interleukin-1β (IL-1β) and IL-18. Methods and Results: This review synthesizes recent experimental and translational research on the role of NLRP3 inflammasome signaling in the pathogenesis of heart failure. It highlights cell-specific mechanisms of activation in cardiomyocytes, fibroblasts, and immune cells, as well as the consequences of sustained inflammasome activity, including myocardial fibrosis, contractile dysfunction, and arrhythmogenesis. Preclinical studies demonstrate that both genetic ablation and pharmacologic inhibition of NLRP3 improve cardiac function and survival in models of ischemic, hypertensive, and diabetic cardiomyopathy. Emerging agents such as MCC950 and dapansutrile offer selective inhibition with promising safety profiles. However, clinical translation remains limited by the need for precise patient selection, validated biomarkers, and long-term efficacy data. Conclusion: Targeting the NLRP3 inflammasome represents a novel and biologically grounded strategy for treating inflammation-driven heart failure. By selectively interrupting a critical inflammatory amplifier, these therapies have the potential to complement existing regimens and address unmet needs in patients with progressive HF.